Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 Nov;59(Suppl 1):i85–i89. doi: 10.1136/ard.59.suppl_1.i85

Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences

J Braun, J Xiang, J Brandt, H Maetzel, H Haibel, P Wu, S Kohler, M Rudwaleit, S Siegert, A Radbruch, A Thiel, J Sieper
PMCID: PMC1766610  PMID: 11053096

Full Text

The Full Text of this article is available as a PDF (142.7 KB).

Figure 1  .

Figure 1  

Open in a new tab

Immunohistological examination of a sacroiliac biopsy specimen obtained by computed tomography guided biopsy of a 23 year old patient with ankylosing spondylitis, four years disease duration, with inflammatory back pain grade 6 on a visual analogue scale (0-10). The red staining indicates a mononuclear cell positive for TNFα (APAAP staining technique).

Figure 2  .

Figure 2  

Open in a new tab

Flow cytometry showing intracellular secretion of TNFα of CD4+ T cells before (left) and one week after treatment with infliximab (right) in a 27 year old patient with ankylosing spondylitis.

Figure 3  .

Figure 3  

Open in a new tab

Magnetic resonance imaging (turbo spin echo sequence) of the spine in a 27 year old patient with ankylosing spondylitis, disease duration 12 years, inflammatory back pain grade 5 on a visual analogue scale (0-10), showing severe spondylitis/spondylodiscitis in the thoracic spine at the levels TH 5/6 and TH 8/9.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amor B., Dougados M., Khan M. A. Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am. 1995 Feb;21(1):117–128. [PubMed] [Google Scholar]
  2. Amor B., Santos R. S., Nahal R., Listrat V., Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994 Oct;21(10):1883–1887. [PubMed] [Google Scholar]
  3. Beutler B. A. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl. 1999 May;57:16–21. [PubMed] [Google Scholar]
  4. Bollow M., Fischer T., Reisshauer H., Backhaus M., Sieper J., Hamm B., Braun J. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis. 2000 Feb;59(2):135–140. doi: 10.1136/ard.59.2.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brahams D. "Repressed memories" and the law. Lancet. 2000 Jul 29;356(9227):358–358. doi: 10.1016/S0140-6736(00)02525-3. [DOI] [PubMed] [Google Scholar]
  6. Brandt J., Bollow M., Häberle J., Rudwaleit M., Eggens U., Distler A., Sieper J., Braun J. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 1999 Sep;38(9):831–836. doi: 10.1093/rheumatology/38.9.831. [DOI] [PubMed] [Google Scholar]
  7. Brandt J., Haibel H., Cornely D., Golder W., Gonzalez J., Reddig J., Thriene W., Sieper J., Braun J. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum. 2000 Jun;43(6):1346–1352. doi: 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  8. Braun J., Bollow M., Neure L., Seipelt E., Seyrekbasan F., Herbst H., Eggens U., Distler A., Sieper J. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995 Apr;38(4):499–505. doi: 10.1002/art.1780380407. [DOI] [PubMed] [Google Scholar]
  9. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  10. Braun J., Bollow M., Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):697–735. doi: 10.1016/s0889-857x(05)70038-7. [DOI] [PubMed] [Google Scholar]
  11. Braun J., Sieper J. Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !? Ann Rheum Dis. 2000 Jun;59(6):404–407. doi: 10.1136/ard.59.6.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Braun J., Sieper J. Inzeptionskohorte für Spondylarthropathien. Z Rheumatol. 2000 Apr;59(2):117–121. doi: 10.1007/s003930050215. [DOI] [PubMed] [Google Scholar]
  13. Braun J., Sieper J. The sacroiliac joint in the spondyloarthropathies. Curr Opin Rheumatol. 1996 Jul;8(4):275–287. doi: 10.1097/00002281-199607000-00003. [DOI] [PubMed] [Google Scholar]
  14. Braun J., Tuszewski M., Ehlers S., Häberle J., Bollow M., Eggens U., Distler A., Sieper J. Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. J Rheumatol. 1997 Jun;24(6):1101–1105. [PubMed] [Google Scholar]
  15. Braun J., Yin Z., Spiller I., Siegert S., Rudwaleit M., Liu L., Radbruch A., Sieper J. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999 Oct;42(10):2039–2044. doi: 10.1002/1529-0131(199910)42:10<2039::AID-ANR3>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  16. Calin A., Nakache J. P., Gueguen A., Zeidler H., Mielants H., Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999 Sep;38(9):878–882. doi: 10.1093/rheumatology/38.9.878. [DOI] [PubMed] [Google Scholar]
  17. Carette S., Graham D., Little H., Rubenstein J., Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 1983 Feb;26(2):186–190. doi: 10.1002/art.1780260210. [DOI] [PubMed] [Google Scholar]
  18. Charles P., Elliott M. J., Davis D., Potter A., Kalden J. R., Antoni C., Breedveld F. C., Smolen J. S., Eberl G., deWoody K. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999 Aug 1;163(3):1521–1528. [PubMed] [Google Scholar]
  19. Cope A. P. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998 Dec;10(6):669–676. doi: 10.1016/s0952-7915(98)80087-3. [DOI] [PubMed] [Google Scholar]
  20. Crilly A., Maiden N., Capell H. A., Madhok R. Genotyping for disease associated HLA DR beta 1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation. Ann Rheum Dis. 1999 Feb;58(2):114–117. doi: 10.1136/ard.58.2.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. De Vos M., Cuvelier C., Mielants H., Veys E., Barbier F., Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology. 1989 Feb;96(2 Pt 1):339–344. doi: 10.1016/0016-5085(89)91557-6. [DOI] [PubMed] [Google Scholar]
  22. Gran J. T., Skomsvoll J. F. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol. 1997 Jul;36(7):766–771. doi: 10.1093/rheumatology/36.7.766. [DOI] [PubMed] [Google Scholar]
  23. Höhler T., Schäper T., Schneider P. M., Meyer zum Büschenfelde K. H., Märker-Hermann E. Association of different tumor necrosis factor alpha promoter allele frequencies with ankylosing spondylitis in HLA-B27 positive individuals. Arthritis Rheum. 1998 Aug;41(8):1489–1492. doi: 10.1002/1529-0131(199808)41:8<1489::AID-ART20>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  24. Kaijzel E. L., Brinkman B. M., van Krugten M. V., Smith L., Huizinga T. W., Verjans G. M., Breedveld F. C., Verweij C. L. Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis. Hum Immunol. 1999 Feb;60(2):140–144. doi: 10.1016/s0198-8859(98)00099-8. [DOI] [PubMed] [Google Scholar]
  25. Leirisalo-Repo M. Prognosis, course of disease, and treatment of the spondyloarthropathies. Rheum Dis Clin North Am. 1998 Nov;24(4):737-51, viii. doi: 10.1016/s0889-857x(05)70039-9. [DOI] [PubMed] [Google Scholar]
  26. Leroux J. Y., Guerassimov A., Cartman A., Delaunay N., Webber C., Rosenberg L. C., Banerjee S., Poole A. R. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J Clin Invest. 1996 Feb 1;97(3):621–632. doi: 10.1172/JCI118458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  28. Maurice M. M., van der Graaff W. L., Leow A., Breedveld F. C., van Lier R. A., Verweij C. L. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999 Oct;42(10):2166–2173. doi: 10.1002/1529-0131(199910)42:10<2166::AID-ANR18>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  29. McGarry F., Walker R., Sturrock R., Field M. The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27. J Rheumatol. 1999 May;26(5):1110–1116. [PubMed] [Google Scholar]
  30. Ohshima S., Saeki Y., Mima T., Sasai M., Nishioka K., Ishida H., Shimizu M., Suemura M., McCloskey R., Kishimoto T. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol. 1999 Sep;19(5):305–313. doi: 10.1023/a:1020543625282. [DOI] [PubMed] [Google Scholar]
  31. Paleolog E. M., Hunt M., Elliott M. J., Feldmann M., Maini R. N., Woody J. N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1082–1091. doi: 10.1002/art.1780390703. [DOI] [PubMed] [Google Scholar]
  32. Present D. H., Rutgeerts P., Targan S., Hanauer S. B., Mayer L., van Hogezand R. A., Podolsky D. K., Sands B. E., Braakman T., DeWoody K. L. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398–1405. doi: 10.1056/NEJM199905063401804. [DOI] [PubMed] [Google Scholar]
  33. Simon A. K., Seipelt E., Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8562–8566. doi: 10.1073/pnas.91.18.8562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Spoorenberg A., de Vlam K., van der Heijde D., de Klerk E., Dougados M., Mielants H., van der Tempel H., Boers M., van der Linden S. Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol. 1999 Apr;26(4):997–1002. [PubMed] [Google Scholar]
  35. Van den Bosch F., Kruithof E., Baeten D., De Keyser F., Mielants H., Veys E. M. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis. 2000 Jun;59(6):428–433. doi: 10.1136/ard.59.6.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Ward M. M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999 Aug;12(4):247–255. [PubMed] [Google Scholar]
  37. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  38. Yin Z., Braun J., Neure L., Wu P., Liu L., Eggens U., Sieper J. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. 1997 Oct;40(10):1788–1797. doi: 10.1002/art.1780401010. [DOI] [PubMed] [Google Scholar]
  39. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES